Circulating microRNAs as molecular biomarkers for lung adenocarcinoma
Cancer Biomarkers · 18.07.2022 · 34 (4) · 591-606
DOI: 10.3233/cbm-210205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, erschienen am 18.07.2022. Verfasst von Irina Robinson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Pulmonology, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Circulating MicroRNA, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: The potential of microRNAs (miRNAs) as molecular tumor biomarkers for early diagnosis and prognosis in lung cancer is still unclear. OBJECTIVE: To analyze expression of miRNAs in A549 lung adenocarcinoma (LUAD) cells and in primary, non-malignant bronchial epithelial (BE) cells from healthy donors. To analyze the most prominently deregulated miRNAs in plasma samples of LUAD patients and healthy donors. MATERIALS AND METHODS: The expression of 752 miRNAs in LUAD and BE cells was assessed by RT-qPCR with mean-centering restricted normalization. The relative plasma levels of 18 miRNAs in LUAD patients and healthy donors were analyzed using RT-qPCR and normalized to miR-191-5p and miR-16-3p. Putative interactions between miRNAs and their target genes were investigated in silico. RESULTS: Out of 752 miRNAs, 37 miRNAs were significantly deregulated in A549 cells compared to BE cells. MiR-15b-3p, miR-148a-3p, miR-193b-3p, and miR-195-5p were significantly deregulated in plasma samples of LUAD patients compared to donors. The target genes of those four miRNAs are involved in essential mechanisms in cancer development and progression. CONCLUSIONS: There are substantial differences between cancer and control miRNA expression in vitro and in plasma samples of LUAD patients compared to healthy donors. Four deregulated miRNAs are promising as a diagnostic biomarker for adenocarcinoma of the lung.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Pulmonology, Medical University of Graz, Graz, Austria.
- BioTechMed-Graz, Graz, Austria.
- Division of Transplantation Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
- Ludwig Boltzmann Institute for Lung Vascular Research, Medical University of Graz, Graz, Austria.
Zitieren
APA
Robinson, I., Bertsch, A., Leithner, K., Stiegler, P., Olschewski, H., & Hrzenjak, A. (2022). Circulating microRNAs as molecular biomarkers for lung adenocarcinoma. Cancer Biomarkers, 34(4), 591-606. https://doi.org/10.3233/cbm-210205
Vancouver
Robinson I, Bertsch A, Leithner K, Stiegler P, Olschewski H, Hrzenjak A. Circulating microRNAs as molecular biomarkers for lung adenocarcinoma. Cancer Biomarkers. 2022;34(4):591-606. doi:10.3233/cbm-210205
BibTeX
@article{Robinson2022,
author = {Robinson, Irina and Bertsch, Alexandra and Leithner, Katharina and Stiegler, Philipp and Olschewski, Horst and Hrzenjak, Andelko},
title = {Circulating microRNAs as molecular biomarkers for lung adenocarcinoma},
journal = {Cancer Biomarkers},
year = {2022},
volume = {34},
number = {4},
pages = {591--606},
doi = {10.3233/cbm-210205}
}
EUVIMED